Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we learn AbbVie has ended its partnership with Calico, the FDA outlines how bespoke gene-editing treatments can make it through the regulatory pipeline, and more. The need-to-know this morning Day One Pharmaceuticals…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got big FDA news to get into today — let’s get straight into it. FDA names Richard Pazdur as top drug regulator The FDA yesterday said it has chosen Richard Pazdur, its…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we just had our first snow of the season in Chicago, I just ordered a pie for Thanksgiving, and I’m still in denial that the year is almost ending. Onto the news…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning, morning. Today, we have a trio of interesting studies on cholesterol reduction from the American Heart Association’s meeting in New Orleans. Also, Pfizer wins the Metsera deal with $10 billion, and we look…
WASHINGTON — When President Trump announced the administration’s deal to cut prices for weight-loss drugs, he proclaimed that “you will pay the lowest price anywhere in the world.” But state Medicaid programs might already be getting lower prices, according to a research firm. Most-favored nation pricing is the main feature of the five deals that the…
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Morning! Lots in biotech today…. New priority review vouchers from the FDA, Mark Cuban rolls out a biosimilar deal, and a patient death is reported in Intellia’s CRISPR trial. Trump’s priority review vouchers…
WASHINGTON — Health Secretary Robert F. Kennedy Jr. was uncharacteristically chummy with pharma executives at the White House on Thursday as he cheered the Trump administration’s plan for lowering obesity medication prices. Kennedy has railed against drugmakers in the past, and his lifestyle-focused “Make America Healthy Again” movement has opposed Medicare coverage of GLP-1 weight loss…
ANDREW CABALLERO-REYNOLDS/AFP via Getty Images Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp.100. Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry…
WASHINGTON — The Trump administration announced a deal Thursday to expand access to popular obesity drugs made by Novo Nordisk and Eli Lilly — offering more coverage for Medicare and Medicaid beneficiaries and lowering the prices across the board. The administration argued that giving millions more people access to these drugs represents a major victory…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Join us later today for a virtual event with STAT’s Jason Mast and Damian Garde about the past and future of Moderna — once one of biotech’s most secretive startups and now, well,…